全文获取类型
收费全文 | 106137篇 |
免费 | 10600篇 |
国内免费 | 7223篇 |
专业分类
耳鼻咽喉 | 974篇 |
儿科学 | 1265篇 |
妇产科学 | 1234篇 |
基础医学 | 12414篇 |
口腔科学 | 2061篇 |
临床医学 | 13556篇 |
内科学 | 15579篇 |
皮肤病学 | 1119篇 |
神经病学 | 5380篇 |
特种医学 | 4242篇 |
外国民族医学 | 69篇 |
外科学 | 10758篇 |
综合类 | 18115篇 |
现状与发展 | 25篇 |
一般理论 | 4篇 |
预防医学 | 7346篇 |
眼科学 | 2840篇 |
药学 | 11393篇 |
107篇 | |
中国医学 | 6526篇 |
肿瘤学 | 8953篇 |
出版年
2024年 | 344篇 |
2023年 | 1573篇 |
2022年 | 4415篇 |
2021年 | 5778篇 |
2020年 | 4138篇 |
2019年 | 3649篇 |
2018年 | 3810篇 |
2017年 | 3534篇 |
2016年 | 3473篇 |
2015年 | 5232篇 |
2014年 | 6246篇 |
2013年 | 5756篇 |
2012年 | 8793篇 |
2011年 | 9144篇 |
2010年 | 6047篇 |
2009年 | 5094篇 |
2008年 | 6113篇 |
2007年 | 5753篇 |
2006年 | 5391篇 |
2005年 | 4879篇 |
2004年 | 3516篇 |
2003年 | 3272篇 |
2002年 | 2807篇 |
2001年 | 2316篇 |
2000年 | 2237篇 |
1999年 | 2122篇 |
1998年 | 1216篇 |
1997年 | 1204篇 |
1996年 | 977篇 |
1995年 | 884篇 |
1994年 | 705篇 |
1993年 | 462篇 |
1992年 | 587篇 |
1991年 | 466篇 |
1990年 | 385篇 |
1989年 | 325篇 |
1988年 | 296篇 |
1987年 | 246篇 |
1986年 | 189篇 |
1985年 | 160篇 |
1984年 | 84篇 |
1983年 | 79篇 |
1982年 | 41篇 |
1981年 | 38篇 |
1980年 | 20篇 |
1979年 | 38篇 |
1978年 | 20篇 |
1973年 | 14篇 |
1970年 | 11篇 |
1969年 | 12篇 |
排序方式: 共有10000条查询结果,搜索用时 93 毫秒
21.
22.
【目的】探讨中药淫羊藿、巴戟天提取物(中药注射液喘可治的组成)对恒河猴单核衍生的巨噬细胞在未极化(M0)、M1极化条件下基因表达的影响,分析其可能的免疫调节的作用机制。【方法】采用密度梯度离心法分离中国恒河猴外周血单个核细胞(PBMCs),采用贴壁法纯化出单核细胞,并以粒细胞巨噬细胞集落刺激因子(GM-CSF)刺激5 d以使单核细胞分化成巨噬细胞;然后不加入极化因子(M0)或以干扰素γ(IFN-γ,继续培养2 d)诱导巨噬细胞极化为M1表型,同时分别加入淫羊藿、巴戟天提取物进行干预;然后提取m RNA并逆转录后,采用实时荧光定量PCR检测CCR5、CD4、CTLA-4、Fox P3、IDO、IL-10、TGF-β等基因表达量。【结果】与空白对照组比较,加入巴戟天提取物培养的M0巨噬细胞基因表达上调不明显;经淫羊藿提取物培养的M0巨噬细胞,CCR5基因表达量上调4.21倍,TGF-β上调7.66倍,Fox P3、IL-10轻度上调,而CD4、CTLA-4、IDO等基因表达改变倍数无明显变化。经巴戟天提取物刺激的M1型巨噬细胞,CTLA-4基因表达量上调3.22倍,Fox P3上调3.69倍,CCR5、CD4、IL-10、IDO基因改变倍数均无明显变化,TGF-β未测出;而由淫羊藿提取物刺激的M1型巨噬细胞,IL-10的表达量上调11.83倍,Fox P3上调4.55倍,IDO、CCR5、CD4、CTLA-4基因改变倍数无明显变化,TGF-β未测出。【结论】巴戟天和淫羊藿提取物培养能够上调M1型巨噬细胞IL-10、Fox P3、CTLA-4等抑炎基因表达,淫羊藿提取物能够上调M0巨噬细胞CCR5和TGF-β等基因表达,促进病原体清除和组织修复,从而发挥多效免疫调节作用。 相似文献
23.
24.
To evaluate the anthropometric indexes in subjects with varicocele compared to controls and the incidence of varicocele in different body mass index (BMI) groups for the purpose of exploring the association between varicocele and anthropometric indexes. A comprehensive literature search was conducted by using PubMed, MEDLINE, EMBASE databases and Cochrane Library up to February 2019. A systematic review and meta‐analysis was conducted by STATA, and Newcastle–Ottawa Scale was utilised for assessing risk of bias. Ultimately, 13 articles containing seven case–control studies and six cross‐sectional studies with 1,385,630 subjects were involved in our study. Pooled results demonstrated that varicocele patients had a lower BMI (WMD = ?0.77, 95% CI = ?1.03 to ?0.51) and a higher height than nonvaricocele participants, especially in grade 3 varicocele patients. Subgroup analyses showed that normal BMI individuals had a higher risk of varicocele than obese or overweight individuals and a lower risk than underweight individuals. In conclusion, this study indicates that varicocele patients have a lower BMI and a higher height than nonvaricocele participants. Moreover, men with excess bodyweight have a lower incidence of varicocele compared to normal weight or underweight people. That is to say, high BMI and adiposity protect against varicocele and high BMI is associated with a decreased risk of varicocele. 相似文献
25.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
26.
目的 通过对公开发表在网络和数据库的有关中医药治疗2019新型冠状病毒肺炎(corona virus disease 2019,COVID-19)的文献进行方、药、证的可视化分析,客观全面的对COVID-19的中医药治疗进行探讨,为现代中医临床诊疗提供参考。方法 本文选用运用文献计量学方法和VOSviewer可视化软件对纳入文献中的用药情况进行数据拆分、整理和分析。结果 本研究高质量数据的主要期刊来源是核心期刊《中医杂志》;新冠临床用方以解表清热剂、开窍补益剂、辟秽祛湿剂为主;临床用药以解表药、清热解毒药、化湿祛痰药以及补益药为主;临床治病思路以六经辨证、三焦辨证和卫气营血辨证理论为指导;临床常见证型为湿、热、寒、毒相关证型;重视新冠前期预防以及后期恢复调养;治疗过程用药考究,注重养阴与祛邪并进。结论 新冠的中医临床诊治考病全面,并注重养阴与祛邪并进,可为官方制定治疗方案提供参考。 相似文献
27.
28.
29.
30.